IMUNON Q1 2024 Financial Results & Business Update Call on May 13, 2024

IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company specializing in DNA-mediated immunotherapy and next-generation vaccines, has announced a conference call scheduled for May 13, 2024, at 11:00 a.m. ET. The purpose of the call is to discuss the financial results for the first quarter ending March 31, 2024, and to provide updates on the company's clinical development programs.

The primary focus will be on IMUNON’s lead clinical program, IMNN-001. This DNA-based interleukin-12 (IL-12) immunotherapy is currently in Phase 2 development for the treatment of first-line, locally advanced-stage ovarian cancer. IMNN-001 stimulates the body to produce significant levels of potent cancer-fighting molecules, particularly interleukin-12 and interferon gamma, directly at the tumor site. This localized approach aims to generate robust and enduring anti-tumor responses.

Additionally, updates will be provided on IMUNON's PlaCCine technology, a novel synthetic DNA delivery system used for developing next-generation vaccines. PlaCCine involves proprietary DNA plasmids designed for the expression of pathogen antigens, aiming to elicit strong immune responses. This technology is promising for creating effective vaccines against various infectious diseases.

The conference call will be accessible to interested parties in North America by dialing 833-816-1132 (toll-free) or 412-317-0711 (international). The call will be available for replay until May 27, 2024, by dialing 877-344-7529 (U.S. toll-free), 855-669-9658 (Canada toll-free), or 412-317-0088 (international), using replay access code 9343581. An audio replay will also be available for 90 days.

IMUNON, headquartered in Lawrenceville, N.J., is dedicated to advancing non-viral DNA technology through two primary modalities: TheraPlas® and PlaCCine®. TheraPlas® focuses on coding proteins and cytokines for treating solid tumors using immunological methods, while PlaCCine® centers on coding viral antigens to provoke strong immune responses, offering a potential platform for vaccines against infectious diseases.

Besides IMNN-001, IMUNON is progressing its COVID-19 booster vaccine, IMNN-101, into a first-in-human study. This initiative is part of the company’s strategy to explore and develop innovative DNA-based immunotherapies and vaccines, leveraging their proprietary technologies to address challenging medical conditions.

IMUNON’s approach harnesses the body's natural mechanisms to produce effective and long-lasting responses, distinguishing it from conventional therapies. The company aims to push the limits of plasmid DNA technology to provide better treatments for patients facing difficult-to-treat diseases.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!